Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03891875 · ClinicalTrials.gov registry record · Phase 2
ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA
A Phase 2 study of Age-related Macular Degeneration, sponsored by Stealth BioTherapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 176
- Enrollment target
- 20
- Study locations
NCT03891875 is a Phase 2 study of Age-related Macular Degeneration that has completed, run by Stealth BioTherapeutics. The registered enrollment target is 176 participants, below the 1,505-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT03891875, a Phase 2 study of Age-related Macular Degeneration, has completed, sponsored by Stealth BioTherapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 176 participants
- Enrollment target
- 20
- Study locations
Study Summary
A randomized, double-masked, placebo-controlled study to evaluate the safety, efficacy and pharmacokinetics of elamipretide in subjects with Age-Related Macular Degeneration with non-central Geographic Atrophy.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Subcutaneous elamipretide through the elamipretide delivery system
- COMBINATION_PRODUCT Subcutaneos placebo through the elamipretide delivery system
Study Locations (20)
Arizona
- Associated Retina Consultants, Ltd. - Peoria
- Retinal Research Institute, LLC - Phoenix
- Arizona Retina & Vitreous Consultants - Phoenix
- Retinal Research Institute, LLC - Phoenix
- Global Retina Institute - Scottsdale
California
- California Retina Consultants - Bakersfield
- Retina-Vitreous Associates Medical Group - Beverly Hills
- Retina Institute of California Medical Group - Palm Desert
- California Retina Consultants - Santa Barbara
- California Retina Consultants - Santa Maria
Florida
- Bascom Palmer Eye Institute - Miami
- MedEye Associates - Miami
- Bascom Palmer Eye Institute - Palm Beach Gardens
- Center for Retina and Macular Disease - Winter Haven
Maryland
- The Retina Care Center - Baltimore
- Cumberland valley retina consultants - Hagerstown
Massachusetts
- Ophthalmic Consultants of Boston - Boston
- New England Retina Consultants - Springfield
Georgia
- Southeast Retina Center, PC - Augusta
Michigan
- Specialty Eye Institute - Jackson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2019-03-27 |
| Est. Completion | 2022-04-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03891875
The ClinicalTrials.gov registry entry for NCT03891875 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,505-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (88% lower). The listed sponsor is Stealth BioTherapeutics, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which Subcutaneous elamipretide through the elamipretide delivery system is the first listed.
NCT03891875 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Arizona, California, Florida.
Frequently Asked Questions
What is clinical trial NCT03891875 about?
NCT03891875 is a clinical study titled "ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA". A randomized, double-masked, placebo-controlled study to evaluate the safety, efficacy and pharmacokinetics of elamipretide in subjects with Age-Related Macular Degeneration with non-central Geographic Atrophy.
What is the current status of trial NCT03891875?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 176 participants. The study started on 2019-03-27. Estimated completion is 2022-04-14.
What conditions does trial NCT03891875 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration.
What interventions are being tested in trial NCT03891875?
The interventions under investigation include: Subcutaneous elamipretide through the elamipretide delivery system (COMBINATION_PRODUCT), Subcutaneos placebo through the elamipretide delivery system (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03891875?
This trial is sponsored by Stealth BioTherapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03891875 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD
RECRUITING · Phase 2
-
A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration
ACTIVE NOT RECRUITING · Phase 2
-
Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
COMPLETED · Phase 2
-
A Study to Evaluate the Safety and Efficacy of RQC for AMD
COMPLETED · Phase 2
-
Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD)
COMPLETED · Phase 2
-
Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.